The big cap empire strikes back
If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
Big cap medtechs see out the decade in style
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
Japanese drugmakers stand out at the nine-month mark
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.
Europe and Asia provide a safe haven as US stocks falter
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
Mid cap device makers find rewards in cancer and diabetes
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Cannabis, M&A and data spur strong gains among small and midcaps
The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Big cap medtech comes roaring back
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
Big cap stocks grow in first half despite M&A activity, not because of it
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
Topsy turvy times for industry’s mid and small cap stocks in the first quarter
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
